CAR-T therapy is available in Germany for the treatment of certain types of blood cancer. In fact, Germany has been a leader in the development and use of CAR-T therapy in Europe.
The use of CAR-T therapy in Germany is regulated by the Federal Institute for Drugs and Medical Devices (BfArM), which oversees the approval and monitoring of all medical treatments and devices in the country. Several CAR-T therapies have been approved by BfArM for use in Germany, including tisagenlecleucel and axicabtagene ciloleucel for the treatment of certain types of blood cancer.

CAR-T therapy is available at several hospitals and clinics in Germany, including university hospitals and specialized cancer centers. Patients who are eligible for CAR-T therapy may be referred to these centers by their treating physician or may seek out treatment at these centers themselves.
In Germany, CAR-T therapy is generally covered by public health insurance, although coverage may vary depending on the specific therapy being used and the patient's insurance policy. Private insurance may also cover some or all of the cost of CAR-T therapy, depending on the specific policy.
Overall, CAR-T therapy is an established and widely available treatment option for eligible patients with certain types of blood cancer in Germany.

Here are some hospitals and clinics in Germany that offer CAR-T therapy:
• University Hospital Würzburg
• University Hospital Carl Gustav Carus Dresden
• University Hospital Frankfurt
• University Hospital Cologne
• University Hospital Heidelberg

CAR-T cell therapy in Israel
CAR-T for Leukemia and Lymphoma in Israel
CAR-T for Myeloma in Israel
CAR-T cell therapy for leukemia and non-Hodgkin's lymphoma (NHL) in Europe
CAR-T cell therapy for Multiple Myeloma patients in Europe